ArticleCancer gene therapy2026
METTL3-mediated m⁶A methylation of E2F2 targets MCU to promote the malignant phenotype of gastric cancer cells.
Article in Cancer gene therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gastric cancer (GC) is a highly prevalent malignancy worldwide, and its progression is closely linked to aberrant epigenetic regulation. E2F transcription factor 2 (E2F2), a member of the E2F transcription factor family, has been identified as an oncogene in various cancers. However, the regulatory effects of epigenetic modifications on E2F2 in GC remain incompletely clarified. To address this knowledge gap, the current study was designed to elucidate the impact of Methyltransferase-like 3 (METTL3)-mediated N⁶-methyladenosine (m⁶A) methylation of E2F2 on mitochondrial function in GC cells by regulating the mitochondrial calcium uniporter (MCU). Both in vitro and in vivo analyses revealed a critical oncogenic axis in GC driven by METTL3. This axis, mediated by m⁶A modification, post-transcriptionally stabilizes E2F2 mRNA, resulting in the upregulation of MCU expression and consequent aberrant mitochondrial calcium uptake. Functional assays revealed that activation of the METTL3/E2F2/MCU axis promotes GC cell proliferation and migration and inhibits apoptosis, whereas knockdown of METTL3 or E2F2 reverses these malignant phenotypes. Mechanistically, METTL3 binds to the 3' untranslated region of E2F2 mRNA to enhance its stability, and E2F2 in turn transcriptionally activates MCU expression. Clinical data analysis indicated positive correlations among METTL3, E2F2, and MCU expression, with high levels associated with poor patient prognosis. These findings suggest that targeting the m⁶A modification pathway holds promise for GC therapy, as the newly identified METTL3-E2F2-MCU axis plays a key role in regulating mitochondrial calcium homeostasis.
Identifiers
42823456What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.